Market Cap 2.76M
Revenue (ttm) 70,000.00
Net Income (ttm) -4.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,271.43%
Debt to Equity Ratio 0.00
Volume 228,700
Avg Vol 1,198,242
Day's Range N/A - N/A
Shares Out 4.48M
Stochastic %K 6%
Beta 0.29
Analysts Strong Sell
Price Target $10.00

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology
Sector: Healthcare
Phone: 718 400 9031
Address:
677 North Washington Boulevard, Sarasota, United States
Eliduderino
Eliduderino Jul. 8 at 11:01 AM
$SILO Uh, I'm just gonna go find a cash machine. Looks like a climber.
0 · Reply
tyrus6
tyrus6 Jul. 7 at 3:10 PM
$ICU WHALE alert! 13G filing I see you there, Mitch! (Mitch has an itch. For ICU.) Here’s what I found on Mitchell P. Kopin (often filing with Intracoastal Capital LLC or alongside Daniel B. Asher), who recently disclosed a 9.99% stake in SeaStar Medical (ICU): --- 👤 Professional Background Founder of Cranshire Capital Advisors LLC (est. 1996) and currently President of Cranshire Capital LP, a private investment firm . **Former President of Downsview Capital, Inc.** . Education: Undergraduate degree from the U. of Illinois and graduate degree from Kellogg School of Management . --- 📈 Investment Strategy & History Mitchell Kopin frequently targets ~5–10% passive stakes in small-cap biotech, med-tech, and tech companies via Schedule 13G filings: Bone Biologics ($BBLG) – 9.99% stake (153K shares) filed June 27, 2025 . Ascent Solar ($ASTI) – 9.99% stake (318K shares) on June 27, 2025 . Processa Pharmaceuticals ($PCSA) – 9.99% on June 17, 2025 . Mitch also scored on $SILO
1 · Reply
aperzy20
aperzy20 Jul. 7 at 1:01 PM
$SILO big news!!! we will fly $MBIO $SONN
0 · Reply
Iiii1ii
Iiii1ii Jul. 7 at 12:31 PM
$SILO 1$+
0 · Reply
DonCorleone77
DonCorleone77 Jul. 7 at 12:31 PM
$SILO Silo Pharma expects preclinical study data on SPC-15 in Q3 Silo Pharma expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 is a novel intranasal prophylactic targeting Post-Traumatic Stress Disorder. The final drug studies are an investigational new drug-enabling GLP-compliant toxicology and toxicokinetic animal study, and a U.S. Food and Drug Administration-requested 7-day safety and toxicology large animal study. Concurrently, a device study of the formulation-specific microchip-based nasal spray system used in SPC-15 is being conducted. Early data on SPC-15 indicated that its optimized patient safety profile and therapeutic delivery may provide additive benefits for combating stress-induced pathophysiology at both the behavioral and neural levels. Eric Weisblum, CEO of Silo, stated, "As we await pre-clinical data within the next 90 days, we currently anticipate initiating the IND application for SPC-15 before the end of the year, assuming positive data results. If submitted and approved, this will be a pivotal achievement along our path to first-in-human trials. If the FDA approves our IND within the 30-day review period, we could initiate a Phase 1 clinical trial before the end of 2026. Moving forward, we intend to seek the FDA's 505(b)(2) regulatory pathway for approval of SPC-15, a drug development route that can significantly shorten clinical timelines for FDA approval and reduce drug development costs."
0 · Reply
JL_TradeZ
JL_TradeZ Jul. 7 at 12:24 PM
$SILO just confirmed preclinical PTSD trial data is coming in Q3 with an IND filing planned for 2025. They also locked in a 50/50 joint venture with HOTH to develop a new obesity therapy licensed from the VA. The float is only 6.2M, MACD just flipped, and volume finally kicked in Thursday. If this reclaims 0.675 with size, we could see it push toward 0.73 and 0.80 with room for more if volume stacks up. Targets: 0.73 / 0.80 / 0.93 Stop: 0.595
0 · Reply
NextBigRun
NextBigRun Jul. 1 at 10:51 PM
$ATER’s setup is insane. Profitable brands, improving margins, insider buying, and AI-powered growth via AIMEE. The float is thin, the market cap is a joke, and shorts are still exposed. All it takes is one catalyst and this flies. Real company. Real upside. $REI $CLVR $SILO $CISO ‘!
1 · Reply
Green_dillo
Green_dillo Jun. 30 at 4:31 PM
$SILO lfg 💦💦
0 · Reply
Abdul92z
Abdul92z Jun. 26 at 9:32 PM
$SILO we need to clear .669 with volume to fly .. of course with news
1 · Reply
prakritim
prakritim Jun. 26 at 4:28 PM
0 · Reply
Latest News on SILO
Silo Pharma Announces Closing of $2 Million Public Offering

May 16, 2025, 4:15 PM EDT - 7 weeks ago

Silo Pharma Announces Closing of $2 Million Public Offering


Silo Pharma Announces Pricing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 7 weeks ago

Silo Pharma Announces Pricing of $2 Million Public Offering


Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 10:50 AM EDT - 1 year ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?


Eliduderino
Eliduderino Jul. 8 at 11:01 AM
$SILO Uh, I'm just gonna go find a cash machine. Looks like a climber.
0 · Reply
tyrus6
tyrus6 Jul. 7 at 3:10 PM
$ICU WHALE alert! 13G filing I see you there, Mitch! (Mitch has an itch. For ICU.) Here’s what I found on Mitchell P. Kopin (often filing with Intracoastal Capital LLC or alongside Daniel B. Asher), who recently disclosed a 9.99% stake in SeaStar Medical (ICU): --- 👤 Professional Background Founder of Cranshire Capital Advisors LLC (est. 1996) and currently President of Cranshire Capital LP, a private investment firm . **Former President of Downsview Capital, Inc.** . Education: Undergraduate degree from the U. of Illinois and graduate degree from Kellogg School of Management . --- 📈 Investment Strategy & History Mitchell Kopin frequently targets ~5–10% passive stakes in small-cap biotech, med-tech, and tech companies via Schedule 13G filings: Bone Biologics ($BBLG) – 9.99% stake (153K shares) filed June 27, 2025 . Ascent Solar ($ASTI) – 9.99% stake (318K shares) on June 27, 2025 . Processa Pharmaceuticals ($PCSA) – 9.99% on June 17, 2025 . Mitch also scored on $SILO
1 · Reply
aperzy20
aperzy20 Jul. 7 at 1:01 PM
$SILO big news!!! we will fly $MBIO $SONN
0 · Reply
Iiii1ii
Iiii1ii Jul. 7 at 12:31 PM
$SILO 1$+
0 · Reply
DonCorleone77
DonCorleone77 Jul. 7 at 12:31 PM
$SILO Silo Pharma expects preclinical study data on SPC-15 in Q3 Silo Pharma expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 is a novel intranasal prophylactic targeting Post-Traumatic Stress Disorder. The final drug studies are an investigational new drug-enabling GLP-compliant toxicology and toxicokinetic animal study, and a U.S. Food and Drug Administration-requested 7-day safety and toxicology large animal study. Concurrently, a device study of the formulation-specific microchip-based nasal spray system used in SPC-15 is being conducted. Early data on SPC-15 indicated that its optimized patient safety profile and therapeutic delivery may provide additive benefits for combating stress-induced pathophysiology at both the behavioral and neural levels. Eric Weisblum, CEO of Silo, stated, "As we await pre-clinical data within the next 90 days, we currently anticipate initiating the IND application for SPC-15 before the end of the year, assuming positive data results. If submitted and approved, this will be a pivotal achievement along our path to first-in-human trials. If the FDA approves our IND within the 30-day review period, we could initiate a Phase 1 clinical trial before the end of 2026. Moving forward, we intend to seek the FDA's 505(b)(2) regulatory pathway for approval of SPC-15, a drug development route that can significantly shorten clinical timelines for FDA approval and reduce drug development costs."
0 · Reply
JL_TradeZ
JL_TradeZ Jul. 7 at 12:24 PM
$SILO just confirmed preclinical PTSD trial data is coming in Q3 with an IND filing planned for 2025. They also locked in a 50/50 joint venture with HOTH to develop a new obesity therapy licensed from the VA. The float is only 6.2M, MACD just flipped, and volume finally kicked in Thursday. If this reclaims 0.675 with size, we could see it push toward 0.73 and 0.80 with room for more if volume stacks up. Targets: 0.73 / 0.80 / 0.93 Stop: 0.595
0 · Reply
NextBigRun
NextBigRun Jul. 1 at 10:51 PM
$ATER’s setup is insane. Profitable brands, improving margins, insider buying, and AI-powered growth via AIMEE. The float is thin, the market cap is a joke, and shorts are still exposed. All it takes is one catalyst and this flies. Real company. Real upside. $REI $CLVR $SILO $CISO ‘!
1 · Reply
Green_dillo
Green_dillo Jun. 30 at 4:31 PM
$SILO lfg 💦💦
0 · Reply
Abdul92z
Abdul92z Jun. 26 at 9:32 PM
$SILO we need to clear .669 with volume to fly .. of course with news
1 · Reply
prakritim
prakritim Jun. 26 at 4:28 PM
0 · Reply
prakritim
prakritim Jun. 26 at 4:28 PM
$SILO banked too
0 · Reply
aperzy20
aperzy20 Jun. 26 at 12:24 PM
0 · Reply
NewsAndFilings
NewsAndFilings Jun. 26 at 12:09 PM
Yesterday's Recap: $SILO Letter of Intent to Form Joint Venture with $HOTH to Develop Obesity Treatment Targeting $16 Billion Global Market $MMMW Three Patent Pending Innovations Reducing Solar Desalination Cost to Be the Same as Tap Water in the $26 Billion Desalination Market
0 · Reply
psm18
psm18 Jun. 25 at 10:37 PM
$SILO Everybody come jump in the Silo with me ! There's psychedelics in here ! 🥴🤑👍💢😏🫡🦄
0 · Reply
Nbdy2u
Nbdy2u Jun. 25 at 3:49 PM
$SILO $RXRX these stocks will go up!!! The entire market today experienced a large dip due to Powell failing to cut interest rates once again, I don’t think Powell will be in the administration much longer!!! Keep holding and buy the dip!
0 · Reply
prakritim
prakritim Jun. 25 at 3:42 PM
$SILO huge money for me here
1 · Reply
prakritim
prakritim Jun. 25 at 3:41 PM
0 · Reply
Arodrcp
Arodrcp Jun. 25 at 2:08 PM
$SILO Exploring Psilocybin’s Role in End-of-Life Care | BJ Miller, M.D. (@bjmillermd) and Bridget Sumser, L.C.S.W. This clip is from episode # 354 of The Drive which was released on 6/23/25. In the full episode, we discuss: -How historical perspectives on death contrast with modern experiences of dying -How proactively engaging with the reality of death can avoid unnecessary suffering and promote a more peaceful ending -How psychedelics like psilocybin can unlock emotional breakthroughs and deepen connection for patients near the end of life -Lessons from the dying on how to live well -Much more Watch or listen (Ep. # 354) to the full episode on my website (peterattiamd.com/bjmillerandbri…) or your favorite podcast player.
0 · Reply
NewsAndFilings
NewsAndFilings Jun. 25 at 2:02 PM
$SILO $HOTH Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market https://www.globenewswire.com/news-release/2025/06/25/3105102/0/en/Silo-Pharma-Enters-into-Letter-of-Intent-to-Form-Joint-Venture-with-Hoth-Therapeutics-to-Develop-Obesity-Treatment-Targeting-16-Billion-Global-Market.html
0 · Reply
Green_dillo
Green_dillo Jun. 25 at 1:58 PM
$SILO lfg
0 · Reply
connorgthecyborg
connorgthecyborg Jun. 25 at 1:39 PM
0 · Reply
defman
defman Jun. 25 at 1:16 PM
$SILO Obesity drug. Americas new addiction. Let's see this thing jgo.
0 · Reply